A novel role for Neurog2 in MYCN driven neuroendocrine plasticity of prostate cancer

Prachi Walke,Jared DW Price,Frederick S Vizeacoumar,Nickson Joseph,Vincent Maranda,Bari Chowdhury,Jay Patel,Yue Zhang,He Dong,Lara New,Ashtalakshmi Ganapathysamy,Li Hui Gong,Hussain Elhasasna,Kalpana K Bhanumathy,Yuliang Wu,Andrew Freywald,Anand Krishnan,Franco Vizeacoumar

DOI: https://doi.org/10.1101/2024.08.16.607954

2024-08-19

Abstract:Neuroendocrine prostate cancer (NEPC) presents a formidable clinical challenge owing to its aggressive progression and resistance to conventional therapies. A key driver of NEPC is the overexpression of MYCN, a well-established oncogene associated with neuroendocrine tumors. However, efforts to directly inhibit the N-Myc protein encoded by this gene have resulted in limited success, thereby hindering therapeutic advancements. To overcome this obstacle, we conducted unbiased genome-wide screening using isogenic prostate cancer cell lines to identify the synthetic vulnerabilities of MYCN. Among the identified candidates, NEUROG2 emerged as a significant candidate. Neurog2 is a proneural transcription factor (PTF) known for its role in developmental processes and trans-differentiation of adult cells. Our findings demonstrate that Neurog2 depletion does not affect non-malignant cells, but significantly suppresses the growth of MYCN-overexpressing cells and tumors in orthotopic NEPC models. Furthermore, our observations indicate that the Neurog2-mediated regulation of PTFs can facilitate NEPC development. Thus, targeting Neurog2 holds promise as an effective therapeutic strategy for MYCN-overexpressing NEPC.

Cancer Biology